Participants’ perspectives of the advanced ovarian cancer biomarker study VALTIVE1: a qualitative study

Holland-Hart, Daniella ORCID: https://orcid.org/0000-0002-1127-5152, Carucci, Margherita, Slusarczyk, Magdalena ORCID: https://orcid.org/0000-0002-4707-7190, Longo, Mirella ORCID: https://orcid.org/0000-0002-9867-3806, Campbell, Susan, Irving, Alys, Noble, Simon ORCID: https://orcid.org/0000-0001-5425-2383, Jayson, Gordon and Hopewell-Kelly, Noreen 2025. Participants’ perspectives of the advanced ovarian cancer biomarker study VALTIVE1: a qualitative study. BMJ Open 15 (7) , e088474. 10.1136/bmjopen-2024-088474

PDF - Published Version Available under License Creative Commons Attribution. Download (372kB)

Abstract

Objectives: VALTIVE1 is a multi-centre, single-arm, non-interventional biomarker study for patients with advanced ovarian cancer. Plasma samples (Tie2 concentration) are collected to detect vascular control in tumours during standard treatment with chemotherapy and bevacizumab. This qualitative study embedded in VALTIVE1 aimed to assess the acceptability and feasibility of a potential VALTIVE2 trial. It explored the participants’ perceptions of the study and treatments and how they might feel if bevacizumab were discontinued based on the results from the biomarker test. Design: This qualitative study used semi-structured telephone interviews, which were analysed using deductive and inductive thematic analysis. Settings: Cancer treatment sites in the UK. Participants: Participants recruited to VALTIVE1 were invited to take part in qualitative interviews. 11 female participants took part from four clinical sites. Results: Participants reported that they experienced side effects attributed to bevacizumab, including stiffness, pain, fatigue, nose bleeds and muscle aches. Participants felt that combining chemotherapy and bevacizumab may have increased the severity of the side effects they experienced. Most participants felt that it was acceptable, if not preferable, to be allocated to a group in a future VALTIVE2 study where bevacizumab may be discontinued according to the results from the biomarker test. A clear preference of participants was to be informed of the biomarker test results, health status and treatment side effects. Conclusion: A future trial should consider ensuring all participants have access to test results, as participants indicated a preference to know whether bevacizumab was working and to discontinue bevacizumab if it had not prevented tumour growth based on the biomarker results. Comprehensive and ongoing information and support regarding treatment side effects should be provided to all participants throughout their cancer pathways and trials. Trial registration number: NCT04523116.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Additional Information:	License information from Publisher: LICENSE 1: URL: https://creativecommons.org/licenses/by/4.0/, Start Date: 2025-07-13, Type: open-access
Publisher:	BMJ Publishing Group
ISSN:	2044-6055
Date of First Compliant Deposit:	22 July 2025
Date of Acceptance:	23 June 2025
Last Modified:	22 Jul 2025 11:02
URI:	https://orca.cardiff.ac.uk/id/eprint/179955

Actions (repository staff only)

Edit Item